Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.

Background: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD.

Objectives: To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse events.

Three year experience with the cochlear BAHA attract implant: a systematic review of the literature.

Background: Bone conduction devices are widely used and indicated in cases of conductive, mixed or single sided deafness where conventional hearing aids are not indicated or tolerated. Percutaneous bone-conduction devices gave satisfactory hearing outcomes but were frequently complicated by soft tissue reactions. Transcutaneous bone conduction devices were developed in order to address some of the issues related to the skin-penetrating abutment.

Developing a one-stop tinnitus service: outcomes of a joined up management strategy: a retrospective observational cohort study.

Rationale, Aims And Objectives: The pressure to deliver quality care with finite resources means that dealing with single-symptom conditions like tinnitus in an efficient and individualized manner has never been more important. Both primary and secondary care practitioners have an obligation to explore efficient delivery of simple management pathways. Commissioners of health care are in a unique position to affect evidence-based strategic change in the management of uncomplicated tinnitus.

Fixed-dose combination therapy for the prevention of cardiovascular disease.

Background: Cardiovascular disease (CVD) is the leading cause of death and disability worldwide, yet CVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure and cholesterol lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of CVD by up to 80% given its potential for better adherence and lower costs.

Objectives: To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood pressure and lipid CVD risk factors for both primary and secondary prevention of CVD.

Allograft tympanoplasty: a historical perspective.

Objective: To present the rise and decline of allograft tympanoplasty and investigate how the challenges it has faced may inform us of its future.

Data Sources: Articles and books published over the last 48 years that refer to allograft tympanoplasty or its historical roots.

History: The first published account of allograft tympanoplasty is by Ned Chalat in 1964; however, whether he was the first to use the technique is controversial.

Cautery of the tympanic membrane: the lesser known history of myringoplasty.

Objective: To present the fascinating, controversial, and tumultuous history of tympanic cautery as a form of myringoplasty and describe the relevance of work more than 150 years old to modern practice and research.

Data Sources: More than 70 English, French, and German articles and books published over the last 400 years, which refer to some aspect of tympanic membrane cautery.

History: The first recorded use of silver nitrate to stimulate closure of tympanic membrane perforations is by William Wilde in 1848.

Fixed-dose combination therapy for the prevention of cardiovascular disease.

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the effectiveness of fixed-dose combination therapy on optimising CVD risk factors and reducing CVD fatal and non-fatal events for both primary and secondary prevention of CVD. Details of CVD events and risk factors included are listed in the methods.